In people with excess weight, pooled weight loss medications (including Saxenda, liraglutide) would become cost-effective only if costs fell by as much as 91%; only Weight Watchers Meetings was cost-effective.
In plain wordsFor people with excess weight, weight loss medicines as a group, liraglutide included, were not cost-effective at current prices.
- Peptide
- Liraglutide
- Outcome
- Not applicableCost-effectiveness of weight loss medications
- Study
n: not reported in source
- Comparator
- Other weight loss interventions
- Outcome group
- Cost-effectiveness · Whole body
Measurements
- Cost decrease needed
- 91%
- medications
Source sentences
Sensitivity analyses revealed that for the medications to become incrementally cost-effective, costs would have to decrease by as much as 91%.
2 context sentences(design, population, supporting numbers)
At an incremental cost-effectiveness ratio of $30 071 per additional QALY gained, only Weight Watchers Meetings was cost-effective.
We identified interventions through a systematic review of randomized controlled trials that reported weight loss 12 months from baseline.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.